This newsletter (attached below) from a leading Indian firm, contains a good review of the perils of the working requirement in India. It also provides a good summary of three recent decisions holding pharma patents invalid for obviousness. What is striking is that the judicial hostility in India to “add-on” drug patents now seems reflected in recent Fed. Cir. opinions that are “anti-patent,” at least as considered by the innovator companies.
Recevie Email Updates